NCT07197671View on ClinicalTrials.gov

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Metastatic Cancer
Interventions
DRUG

90Y-NM600

NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity

Trial Locations (1)

53792

UW Carbone Cancer Center, Madison

Sponsors
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Archeus Technologies, Inc.

UNKNOWN

lead

University of Wisconsin, Madison

OTHER